Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06.

International Journal of Radiation Oncology, Biology, Physics
Susan L TuckerRadhe Mohan

Abstract

To investigate whether the volumes of rectum exposed to intermediate doses, from 30 to 50 Gy, contribute to the risk of Grade ≥ 2 late rectal toxicity among patients with prostate cancer receiving radiotherapy. Data from 1009 patients treated on Radiation Therapy Oncology Group protocol 94-06 were analyzed using three approaches. First, the contribution of intermediate doses to a previously published fit of the Lyman-Kutcher-Burman (LKB) normal tissue complication probability (NTCP) model was determined. Next, the extent to which intermediate doses provide additional risk information, after taking the LKB model into account, was investigated. Third, the proportion of rectum receiving doses higher than a threshold, VDose, was computed for doses ranging from 5 to 85 Gy, and a multivariate Cox proportional hazards model was used to determine which of these parameters were significantly associated with time to Grade ≥ 2 late rectal toxicity. Doses <60 Gy had no detectable impact on the fit of the LKB model, as expected on the basis of the small estimate of the volume parameter (n = 0.077). Furthermore, there was no detectable difference in late rectal toxicity among cohorts with similar risk estimates from the LKB model but with di...Continue Reading

References

Jun 1, 1989·International Journal of Radiation Oncology, Biology, Physics·G J Kutcher, C Burman
Jun 15, 1993·International Journal of Radiation Oncology, Biology, Physics·V A BenkM Goitein
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·J M MichalskiJ D Cox
Feb 15, 2001·International Journal of Radiation Oncology, Biology, Physics·A JacksonC C Ling
Dec 31, 2002·International Journal of Radiation Oncology, Biology, Physics·Derek B ChismGerald E Hanks
Dec 4, 2003·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Carlo GrecoRoberto Orecchia
Mar 6, 2004·International Journal of Radiation Oncology, Biology, Physics·Peter C M KoperPeter Levendag
Jul 21, 2005·International Journal of Radiation Oncology, Biology, Physics·Carlos VargasJohn W Wong
Jan 18, 2006·International Journal of Radiation Oncology, Biology, Physics·Stephanie T H PeetersPeter C M Koper
Jun 17, 2006·Cancer·Sharon H GiordanoJames S Goodwin
Sep 21, 2007·International Journal of Radiation Oncology, Biology, Physics·Claudio FiorinoRiccardo Valdagni
Oct 16, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Gianni FellinRiccardo Valdagni
Mar 5, 2010·International Journal of Radiation Oncology, Biology, Physics·Jeff M MichalskiJoseph O Deasy
Jul 6, 2010·International Journal of Radiation Oncology, Biology, Physics·Susan L TuckerJames D Cox

❮ Previous
Next ❯

Citations

Apr 3, 2013·Current Urology Reports·Phillip J Gray, Jason A Efstathiou
Mar 26, 2013·Journal of Radiation Research·Natsuo TomitaTakeshi Kodaira
Jan 7, 2014·Medical Physics·Kevin L MooreSasa Mutic
Oct 12, 2012·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·H JungT Herrmann
Dec 17, 2014·Radiation Oncology·Daniel Y JohSean P Collins
May 15, 2012·International Journal of Radiation Oncology, Biology, Physics·Susan L TuckerZhongxing Liao
Apr 8, 2015·International Journal of Radiation Oncology, Biology, Physics·Kevin L MooreSasa Mutic
Dec 26, 2012·International Journal of Radiation Oncology, Biology, Physics·Daniel A HamstraFelix Y Feng
Feb 11, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Matthew H StenmarkDaniel A Hamstra
Jun 8, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Susan L TuckerJames D Cox
Jul 21, 2016·American Journal of Clinical Oncology·Mitchell S AnscherNitai D Mukhopadhyay
May 10, 2017·Radiation Oncology·Richard PowisGareth Webster
Sep 30, 2017·International Journal of Health Care Quality Assurance·John SimpsonMatthias Ehrgott

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved